Volume 22 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(3): 357-360
ZHU Ting, HUANG Yafang, XIANG Tong, WU Hao. Application and prospects of cognitive-behavioral therapy based digital therapeutics of chronic disease management in the community[J]. Chinese Journal of General Practice, 2024, 22(3): 357-360. doi: 10.16766/j.cnki.issn.1674-4152.003402
Citation: ZHU Ting, HUANG Yafang, XIANG Tong, WU Hao. Application and prospects of cognitive-behavioral therapy based digital therapeutics of chronic disease management in the community[J]. Chinese Journal of General Practice, 2024, 22(3): 357-360. doi: 10.16766/j.cnki.issn.1674-4152.003402
shu

Application and prospects of cognitive-behavioral therapy based digital therapeutics of chronic disease management in the community

doi: 10.16766/j.cnki.issn.1674-4152.003402

  • School of General Practice and Continuing Education, Capital Medical University, Beijing 100069, China

Funds:

 2022-1-005

  • Received Date: 2023-11-28
    Available Online: 2024-05-27
    Abstract
  • Digital therapeutics, as an emerging effective and safe intervention driven by high-quality software programs, are increasingly being used in primary care based clinical practice. Cognitive-behavioral therapy (CBT) is the most widely used classical approach in psychotherapy and is also a core technology in many digital therapeutics products. CBT interventions are usually limited by the lack of treatment space and professionals, which makes it impossible to reach out to a wider target group of patients. With the help of digital therapeutics, CBT technology can be integrated into the corresponding design module to break through these limitations. At present, CBT-digital therapeutics products are mainly used in the field of primary chronic disease prevention and treatment in the field of lifestyle intervention and patient-centered care, and there is still a large development potential for their application in health monitoring and prevention of common chronic diseases, disease treatment and optimization of drug treatment effects. As an important support to lead the efficient promotion of the quality of primary care services and meet the development of active health technology, CBT-digital therapeutics have ushered in key development opportunities driven by the strong support of the policy environment, the comprehensive technological innovation empowered by emerging technologies, and the increased willingness of patients with chronic diseases to manage their health. At the same time, there are still some key points that need to be broken through and improved in the future of CBT-digital therapeutics. In the future, it is necessary to pay attention to the accumulation of clinical data that meets the needs of supervision, and use algorithm technology to further accurately locate the personalized needs of patients based on patients ' chronic disease data, so as to broaden the indications for chronic disease management of CBT-digital therapeutics. At the same time, it is necessary to further improve the regulatory regulations related to digital therapeutics, formulate an approval system suitable for digital therapeutics products, and improve industry standards in terms of data security, privacy protection, and medical insurance payment policies.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    国务院办公厅. 国务院办公厅关于印发"十四五"国民健康规划的通知[EB/OL]. (2022-05-20)[2023-11-21]. https://www.gov.cn/zhengce/content/2022-05/20/content_5691424.htm.
    [2]
    吕奕鹏, 程帆, 张晓琼, 等. 新时期我国基层公共卫生服务发展现况与展望[J]. 中华全科医学, 2022, 20(10): 1631-1634. doi: 10.16766/j.cnki.issn.1674-4152.002666

    LYU Y P, CHEN F, ZHANG X Q, et al. The current situation and prospect of the primary public health services in China in the new era[J]. Chinese Journal of General Practice, 2022, 20(10): 1631-1634. doi: 10.16766/j.cnki.issn.1674-4152.002666
    [3]
    Digital Therapeutics Alliance. Transforming global healthcare by advancing digital therapeutics 2[EB/OL]. [2023-11-21]. https://dtxalliance.org/.
    [4]
    LUTZ J, OFFIDANI E, TARABOANTA L, et al. Appropriate controls for digital therapeutic clinical trials: a narrative review of control conditions in clinical trials of digital therapeutics (DTx) deploying psychosocial, cognitive, or behavioral content[J]. Front Digit Health, 2022, 4: 823977. DOI: 10.3389/fdgth.2022.823977.
    [5]
    WANG C, LEE C, SHIN H. Digital therapeutics from bench to bedside[J]. NPJ Digit Med, 2023, 6(1): 38. DOI: 10.1038/s41746-023-00777-z.
    [6]
    DANG A, ARORA D, RANE P. Role of digital therapeutics and the changing future of healthcare[J]. J Family Med Prim Care, 2020, 9(5): 2207-2213. doi: 10.4103/jfmpc.jfmpc_105_20
    [7]
    PEGG S, HILL K, ARGIROS A, et al. Cognitive behavioral therapy for anxiety disorders in youth: efficacy, moderators, and new advances in predicting outcomes[J]. Curr Psychiatry Rep, 2022, 24(12): 853-859. doi: 10.1007/s11920-022-01384-7
    [8]
    王晓迪, 罗晓斌, 郭清. 数字疗法在慢性病健康管理中的应用及发展趋势[J]. 中华健康管理学杂志, 2022, 16(1): 51-54.

    WANG X D, LUO X B, GUO Q. Analysis on the application and development trend of digital therapeutics in the health management of chronic diseases[J]. Chinese Journal of Health Management, 2022, 16(1): 51-54.
    [9]
    刘雪, 颜巧元, 周幺玲, 等. 数字疗法用于慢性病管理的研究进展[J]. 护理学杂志, 2023, 38(11): 122-126.

    LIU X, YAN Q Y, ZHOU Y L, et al. Research advances in application of digital therapy in management of chronic diseases[J]. Journal of Nursing Science, 2023, 38(11): 122-126.
    [10]
    CUMMINGS D M, LUTES L D, LITTLEWOOD K, et al. Randomized trial of a tailored cognitive behavioral intervention in type 2 diabetes with comorbid depressive and/or regimen-related distress symptoms: 12-month outcomes from COMRADE[J]. Diabetes Care, 2019, 42(5): 841-848. doi: 10.2337/dc18-1841
    [11]
    VON BRACHEL R, HIRSCHFELD G, BERNER A, et al. Long-term effectiveness of cognitive behavioral therapy in routine outpatient care: a 5- to 20-year follow-up study[J]. Psychother Psychosom, 2019, 88(4): 225-235. doi: 10.1159/000500188
    [12]
    HOLTDIRK F, MEHNERT A, WEISS M, et al. Results of the optimune trial: a randomized controlled trial evaluating a novel internet intervention for breast cancer survivors[J]. PLoS One, 2021, 16(5): e0251276. DOI: 10.1371/journal.pone.0251276.
    [13]
    KARIO K, NOMURA A, HARADA N, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial[J]. Eur Heart J, 2021, 42(40): 4111-4122. doi: 10.1093/eurheartj/ehab559
    [14]
    CANONICO M E, HSIA J, GUTHRIE N L, et al. Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: rationale, design, and baseline characteristics of a randomized, controlled trial[J]. Clin Cardiol, 2022, 45(8): 850-856. doi: 10.1002/clc.23853
    [15]
    MUELLER S, WINZER E B, DUVINAGE A, et al. Effect of high-intensity interval training, moderate continuous training, or guideline-based physical activity advice on peak oxygen consumption in patients with heart failure with preserved ejection fraction: a randomized clinical trial[J]. JAMA, 2021, 325(6): 542-551. doi: 10.1001/jama.2020.26812
    [16]
    RICHARDSON C R, FRANKLIN B, MOY M L, et al. Advances in rehabilitation for chronic diseases: improving health outcomes and function[J]. BMJ, 2019, 365: 12191. DOI: 10.1136/bmj.12191.
    [17]
    AARDEMA F, BOUCHARD S, KOSZYCKI D, et al. Evaluation of inference-based cognitive-behavioral therapy for obsessive-compulsive disorder: a multicenter randomized controlled trial with three treatment modalities[J]. Psychother Psychosom, 2022, 91(5): 348-359. doi: 10.1159/000524425
    [18]
    HSIA J, GUTHRIE N L, LUPINACCI P, et al. Randomized, controlled trial of a digital behavioral therapeutic application to improve glycemic control in adults with type 2 diabetes[J]. Diabetes Care, 2022, 45(12): 2976-2981. doi: 10.2337/dc22-1099
    [19]
    FANG E F, XIE C, SCHENKEL J A, et al. A research agenda for ageing in China in the 21st century (2nd edition): focusing on basic and translational research, long-term care, policy and social networks[J]. Ageing Res Rev, 2020, 64: 101174. DOI: 10.1016/j.arr.2020.101174.
    [20]
    LEAN M E J, LESLIE W S, BARNES A C, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial[J]. Lancet Diabetes Endocrinol, 2019, 7(5): 344-355. doi: 10.1016/S2213-8587(19)30068-3
    [21]
    IRWIN M R, CARRILLO C, SADEGHI N, et al. Prevention of incident and recurrent major depression in older adults with insomnia: a randomized clinical trial[J]. JAMA Psychiatry, 2022, 79(1): 33-41. doi: 10.1001/jamapsychiatry.2021.3422
    [22]
    章汝, 葛孟华, 陈烨君, 等. 基于助推理论的健康管理方案在慢性病患者中的应用[J]. 中华全科医学, 2023, 21(9): 1528-1531, 1536. doi: 10.16766/j.cnki.issn.1674-4152.003162

    ZHANG R, GE Y H, CHEN Y J, et al. Application of health management plan based on boost theory in patients with chronic diseases[J]. Chinese Journal of General Practice, 2023, 21(9): 1528-1531, 1536. doi: 10.16766/j.cnki.issn.1674-4152.003162
    [23]
    HULBERT L R, MICHAEL S L, CHARTER-HARRIS J, et al. Effectiveness of incentives for improving diabetes-related health indicators in chronic disease lifestyle modification programs: a systematic review and meta-analysis[J]. Prev Chronic Dis, 2022, 19: E66. DOI: 10.5888/pcd19.220151.
    [24]
    BERMAN M A, GUTHRIE N L, EDWARDS K L, et al. Change in glycemic control with use of a digital therapeutic in adults with type 2 diabetes: cohort study[J]. JMIR Diabetes, 2018, 3(1): e4. DOI: 10.2196/diabetes.9591.
    [25]
    BITTON A, VEILLARD J H, BASU L, et al. The 5S-5M-5C schematic: transforming primary care inputs to outcomes in low-income and middle-income countries[J]. BMJ Glob Health, 2018, 3(Suppl 3): e001020. DOI: 10.1136/bmjgh-2018-001020.
    [26]
    杨雯. 社区老年慢性病患者保健模式及实施效果分析[J]. 中国保健营养, 2018, 28(20): 292. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201804158.htm

    YANG W. Analysis of the health care model and implementation effect of community-based chronic disease in elderly patients[J]. China Health Care & Nutrition, 2018, 28(20): 292. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYY201804158.htm
    [27]
    MAKIN S. The emerging world of digital therapeutics[J]. Nature, 2019, 573(7775): S106-S109. doi: 10.1038/d41586-019-02873-1
    [28]
    张一帆, 冉琳, 李澍, 等. 精神类疾病数字疗法产品的特殊风险考虑[J]. 中国食品药品监管, 2023(9): 130-137. https://www.cnki.com.cn/Article/CJFDTOTAL-YPJD202309016.htm

    ZHANG Y F, RAN L, LI S, et al. Special risks of digital therapeutics for psychiatric disorders[J]. China Food Drug Administration, 2023(9): 130-137. https://www.cnki.com.cn/Article/CJFDTOTAL-YPJD202309016.htm
    [29]
    国务院办公厅. 国务院办公厅关于发布《国务院办公厅关于促进"互联网+医疗健康"发展的意见》国发办(2018年第26号[EB/OL]. (2018-04-28)[2023-11-21]. https://www.gov.cn/zhengce/content/2018-04/28/content_5286645.htm.
    [30]
    国家药监局. 国家药监局关于进一步加强和完善医疗器械分类管理工作的意见[EB/OL]. (2023-07-19)[2023-11-21]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjylqx/20230719162218145.html.
    [31]
    国家食品药品监督管理总局. 总局发布医疗器械分类目录的公告(2017年第104号)[EB/OL]. (2017-09-04)[2023-11-21]. https://www.nmpa.gov.cn/xxgk/ggtg/ylqxggtg/ylqxqtggtg/20170904150301406.html.
    [32]
    江潇, 张春青, 戎善奎, 等. 数字疗法软件产品分类管理研究[J]. 中国医疗器械杂志, 2023, 47(5): 482-486. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLZ202305003.htm

    JIANG X, ZHANG C Q, RONG S K, et al. Research on the classification management of digital therapeutics software[J]. Chinese Journal of Medical lnstrumentation, 2023, 47(5): 482-486. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYLZ202305003.htm
    [33]
    王晨希, 李澍, 李佳戈. 数字疗法产品质量评价探讨[J]. 中国医疗设备, 2023, 38(4): 25-30. https://www.cnki.com.cn/Article/CJFDTOTAL-YLSX202304005.htm

    WANG C X, LI S, LI J G. Discussion on quality evaluation of digital therapeutics products[J]. Chinese Journal of Medical lnstrumentation, 2023, 38(4): 25-30. https://www.cnki.com.cn/Article/CJFDTOTAL-YLSX202304005.htm
    [34]
    BASCH E. Digital therapeutics for remote symptom monitoring and management in cancer care: the current and future state[J]. Ann Oncol, 2023, 34(8): 635-637.
    [35]
    KIM H S. Apprehensions about excessive belief in digital therapeutics: points of concern excluding merits[J]. J Korean Med Sci, 2020, 35(45): e373. DOI: 10.3346/jkms.2020.35.e373.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (220) PDF downloads(13) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return